A novel isoindole alkaloid named oleraisoindole (1), together with six known compounds, 7'-ethoxy-trans-feruloyltyramine (2), N-trans-feruloyltyramine (3), N-trans-feruloyl-3-methoxytyramine (4), N-trans-p-coumaroyltyramine (5) aurantiamide (6) and ferulic acid methyl ester (7) were isolated from Portulaca oleracea L. Compounds 2 and 7 were isolated for the first time from this plant. Compound 1 was identified using spectroscopic methods including HR-ESI-TOF-MS, 1D-NMR, 2D-NMR. It was tested in a nitric oxide (NO) inhibition assay and was shown to inhibit NO production in RAW 264.7 cells induced by LPS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14786419.2017.1419226 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well-Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's Disease.
Immun Inflamm Dis
December 2024
Department of Rheumatology and Immunology, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
Objective: This study aimed to investigate the efficacy and safety of a triple therapy consisting of colchicine, thalidomide and total glucosides of paeony (TGP) in Behcet's disease (BD) patients with mucocutaneous involvement.
Methods: Totally 355 newly diagnosed BD patients with mucocutaneous involvement were recruited, who received dexamethasone and colchicine for the first 2 weeks, then they were categorized into "sustained triple-therapy (ST)" (n = 231) and "colchicine to triple-therapy (CT)" (n = 124) groups respectively: for ST group, patients received colchicine, thalidomide plus TGP from Month (M)0.5 to M12; for CT group, patients received colchicine from M0.
Erinacenones A-L: Twelve New Isoindolinone Alkaloids from the Edible and Medicinal Mushroom .
Molecules
October 2024
Anhui Province Key Laboratory of Bioactive Natural Products, School of Pharmaceutical Sciences, Anhui University of Chinese Medicine, Hefei 230012, China.
Article Synopsis
- Twelve new isoindolin-1-one compounds, named erinacenones A-L, were discovered from the medicinal fungus through liquid cultures.
- Their structures were determined using various spectroscopic techniques, and the absolute configuration was figured out by comparing optical rotations to literature values.
- Notably, two pairs of these compounds are isomers differing by one double bond, and two of the compounds showed cytotoxic effects against MCF-7 cancer cell lines with IC values of 24.7 and 18.4 μM.
Novel Deep Sea Isoindole Alkaloid FGFC1 Exhibits Its Fibrinolytic Effects by Inhibiting Thrombin-Activatable Fibrinolysis Inhibitor.
Pharmaceuticals (Basel)
October 2024
Department of Marine Bio-Pharmacology, College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.
Background: The thrombin-activatable fibrinolysis inhibitor (TAFI) is an important regulator in the balance between blood clot formation (coagulation) and dissolution (fibrinolysis), which is mainly activated by thrombin bonded with thrombomodulin (TM).
Methods: In this study, the investigation focused on the unique target TAFI of fungi fibrinolytic compound 1 (FGFC1), a novel fibrinolytic compound sourced from the deep sea. In this sense, the regulation of TAFI by FGFC1, in comparison to established TAFI inhibitors such as DS-1040 and PCTI in hPPP, was investigated, which was validated through the molecular docking of FGFC1 to TAFI.
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
J Hematol Oncol
September 2024
Clinical Hematology Unit, Institut Curie, Saint-Cloud, 92210, France.
Background: Results of conventional induction chemotherapies in primary central nervous system lymphoma (PCNSL) need to be improved. Ibrutinib, a BTK inhibitor, and lenalidomide, an immunomodulatory drug, have shown promising results at relapse, supporting to further assess their individual use in combination with high-dose methotrexate-based chemotherapy.
Methods: Patients with newly diagnosed PCNSL were randomized to receive four 28-day cycles of ibrutinib or lenalidomide in combination with R-MPV (rituximab, methotrexate, procarbazine, vincristine and prednisone) in a 3 + 3 design.
Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management.
Am J Hematol
August 2024
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Article Synopsis
- - Plasmablastic lymphoma (PBL) is a rare and aggressive form of lymphoma that is often linked to HIV and immunosuppressed individuals, but can also affect healthy people.
- - Diagnosis of PBL is challenging and requires both clinical suspicion and pathological tests, with particular genetic markers like EBER expression and MYC rearrangements being important for confirmation.
- - Treatment typically involves combination chemotherapy options like EPOCH, and adding drugs such as bortezomib or lenalidomide may enhance patient outcomes; involvement in clinical trials is encouraged for PBL patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!